Adverse outcomes increased with long-term inhaled corticosteroids in COPD
For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Nasal protein could aid in early COPD detection
Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...
Health on MSN21h
What's the Difference Between Asthma and Chronic Obstructive Pulmonary Disease (COPD)?
Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...
Pharmaceutical Technology on MSN3d
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...
News-Medical.Net on MSN4d
Long-term inhaled corticosteroids linked to increased health risks in COPD patients
Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
6abc Action News11d
Balancing COPD with other chronic conditions
Many people with COPD have other conditions like diabetes or high cholesterol, too. Managing several conditions can be ...
Medscape11d
Evidence Growing That GLP-1RAs May Reduce COPD Exacerbations and Risks for Other Lung Diseases
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...
Yahoo Finance3d
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...